Afatinib (Gilotrif, Boehringer Ingelheim) significantly improved outcomes in treatment-naive patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) compared with gefitinib (Iressa, AstraZeneca), with a manageable tolerability profile, according to results of a recent study (Lancet Oncol 2016 Apr 12. [Epub ahead of print], PMID: 27083334).
Results from the LUX-Lung 7 trial showed that afatinib, a second-generation EGFR tyrosine kinase inhibitor,